Innate Pharma S.A.

NASDAQ:IPHA

Biotechnology

Healthcare
$1.33 +1.91%

+$0.03 today

Market cap
$139.83M
Beta
0.89
P/E (TTM)
-3.0
EPS (TTM)
-$0.54
52W Low $1.17High $2.63

Volume 0.09M

Average 0.07M

IPHA EBITDA Margin

EBITDA as a percentage of revenue.

Innate Pharma S.A.NASDAQ: IPHA

EBITDA Margin · Q4 FY2025 · quarter ended Dec 2025

EBITDA Margin widens to 1481.2%

EBITDA Margin was 1481.2% in Q4 FY2025, up 9216.0 pp from a year earlier. Over 3 fiscal years it narrowed by 1544.8 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 3 analysts of 3.4% for the fiscal year ending Dec 2026, up from -1566.1% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
1481.2%— QoQ
Last fiscal yearDec 2025
-1566.1%-1194.4 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+9216.0 pp——
1 year-1194.4 pp+1569.5 pp+2763.9 pp
3 years-1544.8 pp+1618.9 pp+3163.7 pp
5 years+1617.1 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-1566.1%
Year-over-year change
-1194.4pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How IPHA compares with its peers on the latest reported figures

  • IPHA's FY2025 EBITDA Margin of -1566.1% is the 3rd highest of the 5 companies compared; the peer median is -2246.5%.
  • Its year-over-year change of -1194.4 pp is the lowest of 4, against a peer median of +82.8 pp.
  • Over three fiscal years its change of -1544.8 pp compares with a peer median of +491.0 pp.
IPHA Competitors Peer median
EBITDA Margin for IPHA and competitors
Company Period LTM level YoY 3-year change
CGENCompugen Ltd.LTM Mar 202648.0% +82.8 pp+491.0 pp
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026-1053.3% +3016.0 pp—
IPHAInnate Pharma S.A.FY2025-1566.1% -1194.4 pp-1544.8 pp
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026-3439.7% —-2679.5 pp
CRDFCardiff Oncology, Inc.LTM Mar 2026-8329.5% -111.2 pp+2386.2 pp
NVCTNuvectis Pharma, Inc.FY2025— ——
MOLNMolecular Partners AGFY2025— ——
CRBPCorbus Pharmaceuticals Holdings, Inc.FY2025— ——
ELTXElicio Therapeutics, Inc.FY2025— ——
Peer median (excluding IPHA) -2246.5%+82.8 pp+491.0 pp

Competitors are the stored peer set for IPHA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue12.11M57.67M51.9M12.62M2.79M
Cost of Revenue47M51.66M56.02M51.98M0
Gross Profit(22.3M)6.01M5.62M12.62M2.79M
Gross Margin-184.1%10.4%10.8%100.0%100.0%
Research & Development47M51.66M56.02M51.98M43.62M
Selling, General & Admin25.52M14.47M11.75M11.93M11M
Operating Expenses25.52M63.44M18.29M64.2M56.21M
Depreciation & Amortization4.6M45.41M5.09M1.99M5.09M
EBITDA(43.23M)(12.28M)(1.84M)(46.91M)(43.65M)
EBITDA Margin-356.9%-21.3%-3.5%-371.7%-1566.1%
Operating Income(47.83M)(57.43M)(12.67M)(51.58M)(53.43M)
Operating Margin-394.9%-99.6%-24.4%-408.6%-1916.9%
Interest Income327K546K3.18M2.44M1.32M
Interest Expense312K288K640K566K440K
Other Income / Expenses2.35M(547K)5.1M2.1M4.25M
Income Before Tax(45.48M)(57.97M)(7.57M)(49.47M)(49.18M)
Pre-Tax Margin-375.5%-100.5%-14.6%-392.0%-1764.5%
Income Tax Expense00000
Net Income(52.81M)(58.1M)(7.57M)(49.47M)(49.18M)
Net Margin-436.0%-100.7%-14.6%-392.0%-1764.5%
EPS (Basic)(0.57)(0.73)(0.09)(0.61)(0.53)
EPS (Diluted)(0.57)(0.73)(0.09)(0.61)(0.53)
Weighted Avg Shares79.54M79.59M84.11M81.05M89.42M
Weighted Avg Shares (Diluted)79.54M79.64M84.11M81.05M89.42M

Innate Pharma S.A.

NASDAQ:IPHA

Intrinsic Alpha fair value

Locked

Current Price

$1.33

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.